迈威生物：注射用7MW4911临床试验申请获得国家药品监督管理局和美国FDA受理

Core Viewpoint - Maiwei Biotech (688062.SH) has received regulatory approvals for its innovative antibody-drug conjugate (ADC) 7MW4911, marking a significant step in its clinical development [1] Group 1: Regulatory Approvals - The company has received a formal acceptance notice from the National Medical Products Administration (NMPA) for the clinical trial application of 7MW4911 [1] - The U.S. Food and Drug Administration (FDA) has issued an IND Acknowledgement Letter confirming receipt of the IND application for 7MW4911 [1] Group 2: Product Overview - 7MW4911 is developed based on the company's proprietary IDDC? antibody conjugate technology platform, targeting cadherin-17 (CDH17) [1] - CDH17 is identified as a potential therapeutic target validated by multi-omics in various cancers, particularly overexpressed in colorectal, gastric, and pancreatic cancers, which are associated with tumor invasion and poor prognosis [1] Group 3: Mechanism and Design - The ADC features a highly engineered design that integrates three core components: a high-specificity monoclonal antibody Mab0727, a novel cleavable linker, and a proprietary DNA topoisomerase I inhibitor MF-6 [1] - MF-6 is designed to overcome multidrug resistance mechanisms, enhancing antitumor activity through excellent plasma stability, controllable drug release, and a strong bystander effect [1]